David Cameron
Impact in
- Oncology top 0.05%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Bone health and treatments
- Cancer Research top 0.05%
- Breast Cancer Treatment Studies
Papers in
- Oncology 268
- Cancer Treatment and Pharmacology 111
- HER2/EGFR in Cancer Research 103
- Bone health and treatments 34
- Cancer Research 168
- Breast Cancer Treatment Studies 143
- Cancer Genomics and Diagnostics 24
- Co-authors
- Giselle Mann (2 shared papers)Graeme J. Hankey (2 shared papers)J. Michael Dixon (17 shared papers)Martine Piccart (32 shared papers)Charles E. Geyer (13 shared papers)Luca Gianni (10 shared papers)Richard A. Anderson (8 shared papers)W Jack (16 shared papers)
- Journals
- Journal of Clinical Oncology (75 papers)Cancer Research (57 papers)European Journal of Cancer (37 papers)Annals of Oncology (32 papers)British Journal of Cancer (31 papers)
- Partner nations
- United KingdomUnited StatesFrance
In The Last Decade
David Cameron
516 papers receiving 23.8k citations
David Cameron's Hit Papers
Peers
Comparison fields: 5 of 198
- Oncology 10.9k
- Cancer Research 5.7k
- Speech and Hearing 789
- Pulmonary and Respiratory Medicine 3.6k
- Radiology, Nuclear Medicine and Imaging 2.3k
Countries citing papers authored by David Cameron
This map shows the geographic impact of David Cameron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Cameron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Cameron more than expected).
Fields of papers citing papers by David Cameron
This network shows the impact of papers produced by David Cameron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Cameron. The network helps show where David Cameron may publish in the future.
Co-authors
The 25 scholars most cited alongside David Cameron, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 537 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer Hit paper breakdown → | 2006 | 2514 |
| 2 | Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17 Hit paper breakdown → | 2005 | 824 |
| 3 | 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours Hit paper breakdown → | 2010 | 788 |
| 4 | The benefits and harms of breast cancer screening: an independent review Hit paper breakdown → | 2013 | 742 |
| 5 | 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial Hit paper breakdown → | 2017 | 704 |
| 6 | Triple-negative breast cancer: disease entity or title of convenience? Hit paper breakdown → | 2010 | 657 |
| 7 | Swallowing Function After Stroke Hit paper breakdown → | 1999 | 631 |
| 8 | Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial Hit paper breakdown → | 2015 | 610 |
| 9 | Identification of molecular apocrine breast tumours by microarray analysis Hit paper breakdown → | 2005 | 586 |
| 10 | 2009 | 485 | |
| 11 | 2006 | 369 | |
| 12 | 2011 | 358 | |
| 13 | 1999 | 345 | |
| 14 | 2000 | 291 | |
| 15 | 2006 | 288 | |
| 16 | 2006 | 279 | |
| 17 | 2005 | 259 | |
| 18 | 2008 | 230 | |
| 19 | 2010 | 229 | |
| 20 | 2011 | 210 |
About David Cameron
David Cameron is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Molecular Biology and Genetics, having authored 537 papers that have together received 24.5k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (143 papers), Cancer Treatment and Pharmacology (111 papers), HER2/EGFR in Cancer Research (103 papers), Advanced Breast Cancer Therapies (91 papers), Estrogen and related hormone effects (39 papers), Bone health and treatments (34 papers), Retinal Development and Disorders (27 papers) and Cancer Genomics and Diagnostics (24 papers). The work is most often cited by research in Oncology (10.9k citations), Cancer Research (5.7k citations), Speech and Hearing (789 citations), Pulmonary and Respiratory Medicine (3.6k citations) and Radiology, Nuclear Medicine and Imaging (2.3k citations). David Cameron has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Giselle Mann, Graeme J. Hankey, J. Michael Dixon, Martine Piccart, Charles E. Geyer, Luca Gianni, Richard A. Anderson, W Jack, Cristina Oliva and Steven Stein. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, European Journal of Cancer, Annals of Oncology and British Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.